(Press-News.org) A study of more than 1,000 patients with colon cancer that had spread to distant sites found that one in eight was treated with at least one drug regimen that was not recommended. Those patients were exposed to significant risk without proven benefits, at an estimated cost—just for the drugs—of more than $2 million.
The study, presented June 7, 2011, by University of Chicago researchers at the American Society for Clinical Oncology's annual meeting in Chicago, focused on three chemotherapy regimens that were not supported by evidence from prior clinical studies or clinical practice guidelines. One treatment was rated "insufficient data to support," one had been "shown to be ineffective," and one was supported by "no data, nor is there a compelling rationale."
"Patients with advanced cancers that do not respond to standard therapies should either be looking for clinical trials, where there is a chance for a benefit, or should have been thinking about shifting toward palliative care," said study author Jonas De Souza, M.D., a hematology/oncology fellow at the University of Chicago. "Patients should not face the risks, discomforts and costs of aggressive and often quite toxic chemotherapy with treatment regimens that did not provide a benefit in previous studies."
Under an agreement with UnitedHealthcare, a health benefits business, the researchers used de-identified medical and pharmaceutical claims data in the collaborative project. They examined claims from 7,642 colon cancer cases treated between January 2007 and June 2010, including 1,041 who developed metastatic disease. Of those 1,041 patients, 140 (13%) received treatments that were not supported by the evidence from clinical studies. Many of them received multiple cycles of non-beneficial chemotherapy.
The researchers focused on three chemotherapy regimens with specific recommendations against their use in the National Comprehensive Cancer Network (NCCN) guidelines. The regimen with insufficient data involved bevacizumab (trade name Avastin) used after the patient had progressed on a combination of that drug and chemotherapy. The treatment shown to be "ineffective" was capecitabine (trade name Xeloda) after progression on the same class of drugs. The regimen with no compelling rationale was panitumumab or cetuximab (trade name Erbitux) after progression on similar drugs.
The 140 patients received 869 cycles of chemotherapy. Some received two or more unproven treatments.
Ninety-one of those patients went through 632 intravenous cycles of bevacizumab, at an estimated cost of $1.3 million. Potential side effects include hypertension, heightened risk of bleeding and bowel perforation.
Fifty-nine patients received 218 non-evidence-based cycles of capecitabine, at a cost of more than $600,000. This drug, taken orally, can cause diarrhea, nausea, vomiting, fatigue, rash and swelling of the hands or feet.
Six patients underwent 19 cycles of panitumumab, at a cost of almost $70,000. This drug can trigger itching, dermatitis and rash.
"We did not study why these physicians and patients turned to unproven therapies," said co-author Caleb Alexander, M.D., associate professor of medicine at the University of Chicago. "I suspect that both patients and care providers, when facing life-threatening disease with limited options, are more willing to step outside guidelines."
"There could also be financial implications," he added. "A physician who has run out of options may be hesitant to send a patient to a center that has access to greater resources but may be far away."
The researchers emphasized, however, that as the costs of cancer care continue to rise, the impetus to base treatment decisions on solid evidence can only increase. "It's important to get the right medicines to the right patients," said Alexander.
"DeSouza's research highlights the importance of evidence-based treatment for cancer patients," said Lee Newcomer, M.D., UnitedHealthcare's senior vice president, oncology. "Expert oncology opinions tell us that the extra therapies that these patients received potentially exposed these patients to unnecessary side effects. We should be relieving symptoms and not causing new ones, even as we try to address the underlying disease."
### END
Many patients with advanced cancers get treatments that won't help
2011-06-08
ELSE PRESS RELEASES FROM THIS DATE:
33-country survey reports 50 percent increase in sustainably managed tropical forests
2011-06-08
BERN, SWITZERLAND (7 JUNE 2011)—A comprehensive assessment of tropical forest management reports a 50 percent increase in the area of tropical forest under sustainable management in just five years, but cautions that key drivers of that increase—growing demand for certified timber and funding for climate change initiatives—could have only a marginal impact in the long-term.
Drawing on detailed data on each of the 33 countries that together control almost all of the world's tropical rainforests and tropical timber production, the report released today by the Japan-based ...
Mapping anemia risk in preschool-age children in West Africa
2011-06-08
In this week's PLoS Medicine, Ricardo Soares Magalhães and Archie Clements, from the University of Queensland, Brisbane, Australia, describe how they used national cross-sectional household-based demographic health surveys to map the distribution of anaemia risk in preschool-age children in Burkina Faso, Ghana, and Mali. The use of such maps has significant practical implications for targeted control of anaemia in these countries, such as guiding the efficient allocation of nutrient supplements and fortified foods, and contributing to the planning and evaluation of resource ...
Coseasonality of influenza and invasive pneumococcal disease
2011-06-08
Using a combination of sophisticated modelling and statistical analyses, David Fisman and colleagues show that infection with influenza likely increases the incidence of invasive pneumococcal disease (IPD). It is feasible that infection with influenza increases the short-term risk of bacterial invasion in individuals already colonized with Streptococcus pneumoniae (which causes IPD) by increasing the permeability of the lining of the airways to the bacteria. These findings suggest that some cases of IPD could be attributable to influenza, so the extension of influenza ...
Health and safety of low-skilled workers should be priority for migration policy
2011-06-08
In the fourth article in a six-part PLoS Medicine series on migration & health, Joan Benach from the Employment Conditions Network at the Universitat Pompeu Fabra, Barcelona, Spain, and colleagues discuss the health risks and policy needs associated with migration to destination countries, especially for low-skilled workers. In destination countries, migrant workers often fill low- or semi-skilled positions in the labour market, which are often characterized by flexibility, insecurity, precarious employment, and long working hours with low pay. Undocumented or "illegal" ...
Finnish twin study yields new information on how fat cells cope with obesity
2011-06-08
The mechanisms by which obesity leads towards metabolic co-morbidities, such as diabetes mellitus, are poorly understood and of great public health interest. A study led by Matej Orešič from VTT Technical Research Centre of Finland suggests that adaptation of fat cell membranes to obesity may play a key role in the early stages of inflammatory disorders.
Millions of adults are diagnosed as obese each year, worldwide. Many of these people suffer from a disorder known as metabolic syndrome, which includes symptoms such as hypertension and elevated blood cholesterol. ...
Apple ingredient keeps muscles strong
2011-06-08
In search of a way to prevent the muscle wasting that comes with illness and aging, researchers have landed a natural compound that might just do the trick. The findings reported in the June issue of Cell Metabolism, a Cell Press publication, identify a component of apple peels as a promising new drug candidate for the widespread and debilitating condition that affects nearly everyone at one time or another.
"Muscle wasting is a frequent companion of illness and aging," said Christopher Adams of The University of Iowa, Iowa City. "It prolongs hospitalization, delays ...
Study links insulin action on brain's reward circuitry to obesity
2011-06-08
Researchers reporting in the June issue of Cell Metabolism, a Cell Press publication, have what they say is some of the first solid proof that insulin has direct effects on the reward circuitry of the brain. Mice whose reward centers can no longer respond to insulin eat more and become obese, they show.
The findings suggest that insulin resistance might help to explain why those who are obese may find it so difficult to resist the temptation of food and take the weight back off.
"Once you become obese or slide into a positive energy balance, insulin resistance in ...
Apple peel makes mice mighty
2011-06-08
For Popeye, spinach was the key to extra muscle. For the mice in a new University of Iowa study, it was apples, or more precisely a waxy substance called ursolic acid that's found in apple peel.
The UI study, published in the June 8 issue of the journal Cell Metabolism, showed that ursolic acid reduced muscle atrophy (also known as muscle wasting) and promoted muscle growth in mice. It also reduced fat, blood sugar levels, cholesterol and triglycerides in the animals. The findings suggest that the compound may be useful for treating muscle wasting and possibly metabolic ...
UCSF finds new bee viruses, offers baseline to study colony collapse
2011-06-08
A 10-month study of healthy honey bees by University of California, San Francisco scientists has identified four new viruses that infect bees, while revealing that each of the viruses or bacteria previously linked to colony collapse is present in healthy hives as well.
The study followed 20 colonies in a commercial beekeeping operation of more than 70,000 hives as they were transported across the country pollinating crops, to answer one basic question: what viruses and bacteria exist in a normal colony throughout the year?
The results depict a distinct pattern of infections ...
Bone cancer, from the lab to the clinic
2011-06-08
A new study into osteosarcoma - cancer of the bone - will use advances in genomic research and analysis to identify new genes that give rise to the condition and to create personalised blood tests for children and young adults with the condition. The study is funded by Skeletal Action Cancer Trust, SCAT.
It is hoped that the results of this new study will help doctors improve treatment of this difficult disease through better diagnosis and monitoring of this bone cancer.
Each year approximately 80 children and young adults develop osteosarcoma in the UK. This painful ...